A Phase 1a Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study Assessing Safety and Immunogenicity of Px563L and RPA563 Administered by Intramuscular Injection in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Px 563L (Primary)
- Indications Anthrax
- Focus Adverse reactions
- Sponsors Pfenex
- 07 Jul 2017 Status changed from active, no longer recruiting to completed.
- 08 Aug 2016 According to Pfenex media release, the company announced results from day 70 analysis of anthrax vaccine study .
- 03 May 2016 Status changed from recruiting to active, no longer recruiting.